Evommune CEO Luis C. Pena amends two stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Evommune, Inc. (EVMN) reported that President & CEO Luis C. Pena amended two stock options on November 13, 2026. Each old option was deemed canceled and replaced by an option covering the same number of underlying shares. The replacement option covering 796,841 shares has an exercise price of $7.63 per share, compared with $16.00 for the canceled option; the replacement covering 291,420 shares also has an exercise price of $7.63 per share, compared with $26.77 for the canceled option.
For either replacement option, an exercise before the earliest of November 13, 2027, a Change in Control, or certain specified employment-related events carries a premium exercise price equal to the original exercise price. The 796,841-share option’s first quarter vested on November 5, 2026, with the remainder vesting in 36 equal monthly installments. The 291,420-share option’s first quarter is scheduled to vest on April 16, 2027, followed by 36 equal monthly installments. Vesting is subject to continuous service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to buy) F1, F2, F3 | 796,841 | -- | -- |
| Grant/Award | Stock Option (Right to buy) F1, F2, F3 | 796,841 | -- | -- |
| Disposition | Stock Option (Right to buy) F4, F2, F5 | 291,420 | -- | -- |
| Grant/Award | Stock Option (Right to buy) F4, F2, F5 | 291,420 | -- | -- |
Footnotes (5)
- F1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
- F2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
- F3. One fourth (1/4) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- F4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 16, 2026.
- F5. One fourth (1/4) of the shares subject to the option award shall vest on April 16, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Key Terms
Option Repricing technical
Change in Control technical
Good Reason technical
continuous service technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What option changes did Evommune (EVMN) CEO Luis C. Pena report?
When do Luis C. Pena’s replacement options expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.